Ad­lai Nortye ac­quires global rights to No­var­tis cancer drug

BioSpectrum (Asia) - - Company News -

China based Ad­lai Nortye Bio­pharma Co., Ltd., a bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to dis­cov­er­ing and com­mer­cial­iz­ing new drugs in the field of on­col­ogy/im­muno-on­col­ogy, has an­nounced that it has en­tered into a Global Li­cense Agree­ment with No­var­tis Pharma AG, a global phar­ma­ceu­ti­cal com­pany. Un­der the terms of the Agree­ment, ex­cept for cer­tain rights main­tained by No­var­tis Pharma AG, Ad­lai Nortye will have ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights to bu­parlisib world­wide for all the ther­a­peu­tic, pro­phy­lac­tic and/or di­ag­nos­tic uses in hu­mans. Bu­parlisib (BKM120) is an oral pan-PI3K in­hibitor that tar­gets all class 1 PI3K iso­forms and is ac­tive in both hema­to­logic ma­lig­nan­cies and solid tu­mors. It has shown promis­ing ef­fi­cacy in com­bi­na­tion with pa­cli­taxel in head and neck squa­mous cell car­ci­noma (HNSCC) and has re­ceived a Fast-Track des­ig­na­tion from the FDA.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.